deltatrials
Active Not Recruiting PHASE3 INTERVENTIONAL 2-arm NCT03869892

Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy. (SOLSTICE)

An Open-label, Randomised, Phase III Study cOmparing trifLuridine/Tipiracil (S 95005) in Combination With Bevacizumab to Capecitabine in Combination With Bevacizumab in firST-line Treatment of Patients With metastatIC Colorectal Cancer Who Are Not candidatE for Intensive Therapy (SOLSTICE Study)

Sponsor: ADIR, a Servier Group company

Conditions Metastatic Colorectal Cancer
Interventions Bevacizumab control Bevacizumab experimental Capecitabine Trifluridine/tipiracil hydrochloride (S95005)
Updated 19 times since 2019 Last updated: Dec 15, 2025 Started: Mar 21, 2019 Primary completion: Jun 29, 2021 Completion: Dec 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Metastatic Colorectal Cancer and is currently ongoing. ADIR, a Servier Group company leads this study, which shows 19 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Apr 2019 – ~Jun 2019 · 2 months · monthly snapshot~Jun 2019 – ~Oct 2019 · 4 months · monthly snapshot~Oct 2019 – ~Dec 2019 · 2 months · monthly snapshot~Dec 2019 – ~Feb 2020 · 2 months · monthly snapshot~Feb 2020 – ~Oct 2020 · 8 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Jan 2022 · 12 months · monthly snapshot~Jan 2022 – ~May 2022 · 4 months · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Jan 2023 · 7 months · monthly snapshot~Jan 2023 – ~May 2023 · 4 months · monthly snapshot~May 2023 – ~Nov 2023 · 6 months · monthly snapshot~Nov 2023 – ~Dec 2023 · 30 days · monthly snapshot~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jan 2025 · 4 months · monthly snapshot~Jan 2025 – ~Sep 2025 · 8 months · monthly snapshot~Sep 2025 – ~Jan 2026 · 4 months · monthly snapshot~Jan 2026 – present · 5 months · monthly snapshot

Change History

19 versions recorded

  1. Jan 2026 — Present [monthly]

    Active Not Recruiting PHASE3

  2. Sep 2025 — Jan 2026 [monthly]

    Active Not Recruiting PHASE3

  3. Jan 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE3

  4. Sep 2024 — Jan 2025 [monthly]

    Active Not Recruiting PHASE3

  5. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE3

▶ Show 14 earlier versions

  1. Dec 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE3

  2. Nov 2023 — Dec 2023 [monthly]

    Active Not Recruiting PHASE3

    Status: Completed → Active Not Recruiting

  3. May 2023 — Nov 2023 [monthly]

    Completed PHASE3

  4. Jan 2023 — May 2023 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  5. Jun 2022 — Jan 2023 [monthly]

    Active Not Recruiting PHASE3

  6. May 2022 — Jun 2022 [monthly]

    Active Not Recruiting PHASE3

  7. Jan 2022 — May 2022 [monthly]

    Active Not Recruiting PHASE3

  8. Jan 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE3

  9. Oct 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  10. Feb 2020 — Oct 2020 [monthly]

    Recruiting PHASE3

  11. Dec 2019 — Feb 2020 [monthly]

    Recruiting PHASE3

  12. Oct 2019 — Dec 2019 [monthly]

    Recruiting PHASE3

  13. Jun 2019 — Oct 2019 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  14. Apr 2019 — Jun 2019 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Mar 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • ADIR, a Servier Group company
  • Institut de Recherches Internationales Servier
Data source: Servier

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalborg, Denmark , Aberdeen, United Kingdom , Alicante, Spain , Almada, Portugal , Arkhangelsk, Russia , Arnhem, Netherlands , Avignon, France , Badalona, Spain , Barcelona, Spain , Barretos, Brazil and 143 more locations